Adagrasib
As of the edition of 20 October 2026, Adagrasib is a small molecule: marketed, first approved in 2022 (US); acts on KRAS; US protection ends in 2041.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Krazati
- First approved
- 12 December 2022 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 35, 9 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2041.
The last listed US drug-substance patent ends in 2041. The application that gives this date is held by Bristol Myers Squibb.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product5 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 5 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Adagrasib.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KRAS | GTPase KRas | P01116 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 17 | 3 | 6 | 7 |
| Phase 2 | 13 | 1 | 10 | 2 |
| Phase 3 | 4 | 0 | 4 | 0 |
| All trials | 35 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator, Applicant and Lead sponsor of trials | 2019 to now |